Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 06 December 2016

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Nucleoside analogues lowers recurrence risk in HBV−related HCC after resection

A study in this week's issue of the Journal of the American Medical Association investigates the use of nucleoside analogues and the risk of Hepatitis B virus–related hepatocellular carcinoma recurrence following liver resection.

News image

Tumor recurrence is a major issue for patients with hepatocellular carcinoma following curative liver resection.

Dr Chun-Ying Wu and colleagues investigated the association between nucleoside analogue use and risk of tumor recurrence in patients with hepatitis B virus (HBV)−related hepatocellular carcinoma (HCC) after curative surgery.

The researchers conducted a nationwide cohort study between 2003 and 2010.

Data from the Taiwan National Health Insurance Research Database.

The 6-year overall mortalities for treated cohorts were 29%
Journal of the American Medical Association

Among 100,938 newly diagnosed hepatocellular carcinoma patients, the team identified 4569 HBV-related hepatocellular carcinoma patients who received curative liver resection for hepatocellular carcinoma between 2003 and 2010.

The team's main outcome measures included the risk of first tumor recurrence compared between patients not taking nucleoside analogues, and patients taking nucleoside analogues.

The research team found that the treated cohort had a higher prevalence of liver cirrhosis when compared with the untreated cohort, but lower risk of hepatocellular carcinoma recurrence, and lower overall death.

After adjusting for competing mortality, the treated cohort had a significantly lower 6-year hepatocellular carcinoma recurrence rate.

The team found that the 6-year overall mortalities for treated cohorts were 29%,and for untreated 42%.

The researchers observed that nucleoside analogue use, statin use, and nonsteroidal anti-inflammatory drugs or aspirin use were independently associated with a reduced risk of hepatocellular carcinoma recurrence.

The researchers verified the association in all subgroups of patients, including those who were noncirrhotic, and diabetic.

Dr Wu's team concludes, "Nucleoside analogue use was associated with a lower risk of hepatocellular carcinoma recurrence among patients with HBV-related hepatocellular carcinoma after liver resection."

JAMA 2012; 308(18): 1906-1913
15 November 2012

Go to top of page Email this page Email this page to a colleague

 06 December 2016 
IBD Disability Index in restorative proctocolectomy
 06 December 2016 
Anti-TNF therapy for IBD
 06 December 2016 
Crohn's disease and thyroid cancer risk
 05 December 2016 
Disease mangement in IBD
 05 December 2016 
New biomarkers for IBD diagnosis
 05 December 2016 
Reducing hospitalization in IBD
 02 December 2016 
Hep E in acute liver failure
 02 December 2016 
Occurrence and severity of alcoholic hepatitis
 02 December 2016 
Food antigen in active eosinophilic esophagitis
 01 December 2016 
Iron deficiency in anemic ulcerative colitis patients
 01 December 2016 
Prognostic factors after paracetamol-induced liver failure
 01 December 2016 
Factors that influence colorectal cancer screening findings
 30 November 2016 
Certolizumab pegol in Crohn's disease
 30 November 2016 
Genetic risk of Crohn's in chronic granulomatous disease
 30 November 2016 
Rifaximin in diarrhea-predominant IBS
 29 November 2016 
Assessing liver steatosis
 29 November 2016 
Treating Zenker's diverticulum
 29 November 2016 
Colorectal cancer surveillance in ulcerative colitis
 28 November 2016 
Complications in celiac disease
 28 November 2016 
Monitoring IBD with mobile technology
 28 November 2016 
Reducing warfarin-related upper GI bleeds
 25 November 2016 
Metal vs plastic stents for pancreatic cancer surgery
 25 November 2016 
Yoga and IBS therapy 
 25 November 2016 
Colorectal cancer screening issues
 24 November 2016 
Partner burden in celiac disease
 24 November 2016 
Fusobacterium nucleatum for colorectal cancer prognosis
 24 November 2016 
PPIS and gastric cancer risk
 23 November 2016 
Diagnosing autoimmune pancreatitis
 23 November 2016 
Readmissions in cirrhosis
 23 November 2016 
Quality assurance standards for colonoscopy
 22 November 2016 
Fatigue in IBD
 22 November 2016 
PPIs and C. diff in ICU 
 22 November 2016 
Bile acid diarrhea in function bowel disorder with diarrhea
 21 November 2016 
Financial incentives and colorectal cancer screening
 21 November 2016 
Pain after endoscopic resection of gastric tumors
 21 November 2016 
Antivirals and chemotherapy in Hep C patients with cancer
 18 November 2016 
Colorectal cancer risk and self-reported family history
 18 November 2016 
Ustekinumab in Crohn’s disease
 18 November 2016 
Antivirals and chemotherapy in Hep C patients with cancer
 17 November 2016 
Risk of overweight in infants
 17 November 2016 
Moderate alcohol consumption and NAFLD
 17 November 2016 
Liver-related specialty care in patients with Hep C
 16 November 2016 
PPI therapy in liver disease
 16 November 2016 
Education in Gastroenterology fellowship
 16 November 2016 
Paternal preconceptional use of anti-TNF-α agents
 15 November 2016 
Novel treatment of NASH 
 15 November 2016 
Physician perspectives on Hep C management
 15 November 2016 
Contraceptives and ulcerative colitis
 14 November 2016 
Cardiovascular risk in NAFLD 
 14 November 2016 
Vit D and NAFLD
 14 November 2016 
Malignancy risk in IBD 
 11 November 2016 
Treatment of Hep C along with opioid agonist therapy
 11 November 2016 
Diabetes and liver cancer risk in Hep C cirrhosis
 11 November 2016 
Biomarker of cirrhosis progression
 10 November 2016 
Testosterone levels and cirrhosis outcomes in men
 10 November 2016 
Improving bowel quality before colonoscopy
 10 November 2016 
Fecal microbiota transplantation and CDI episodes
 09 November 2016 
Minimizing costs of esophagogastroduodenoscopy and colonoscopy
 09 November 2016 
Risk of TB in IBD patients receiving therapy
 09 November 2016 
Liver transplant wait-list and mortality in infants

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2016 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us